

## PUBLIC SUMMARY DOCUMENT

**Product:** Dansac Nova 2

**Applicant:** Dansac

**Date of SPAP Meeting:** 12 October 2021

### 1. Proposed Deletion on the Stoma Appliance Scheme

The applicant, Dansac, sought the deletion of one variant of Dansac Nova 2 (SAS Code 3865K) in subgroup 4(a) of the Stoma Appliance Scheme (the Scheme) Schedule, due to the variant being discontinued. The product, including 12 variants, is currently listed at a unit price of \$4.142, with a maximum monthly quantity of 30 units.

### 2. Substitute products

The nominated substitute product is a variant of Dansac NovaLife TRE Flat Baseplate (SAS Code 80201D) in the same subgroup. The product, including eight variants, is currently listed at a unit price of \$4.142, with a maximum monthly quantity of 30 units.

#### Variant to be deleted

Product Code	Description
1136-15	mechanical coupling, 36mm ring, 1.65mm, hydrocolloid baseplate, flat, self-adhesive, standard wear, diamond, cut-to-fit, 15mm, 28mm,

#### Nominated substitute – SAS Code 80201D

Product Code	Description
3136-15	belt loops on each side of the pouch, mechanical coupling, 36mm ring, floating flange, 0.7mm, hydrocolloid baseplate, hydrocolloid self-adhesive, standard wear, oval, cut-to-fit, 15mm, release tabs, 28mm,

### 3. Background

This product was first listed on the Scheme Schedule on 1 April 2011.

### 4. Clinical Place for the Product

The proposed substitute product provides an alternative for users requiring a two-piece baseplate pouch with flat mechanical coupling.

#### Financial Analysis

The substitute product is currently listed in subgroup 4(a) of the Scheme Schedule at the same cost and maximum monthly quantity. It is therefore, unlikely that there would be any budgetary impact for the Scheme as a consequence of deleting this variant.

### 5. Panel Recommendation

The Panel recommended the deletion of one variant of Dansac Nova 2 (SAS Code 3865K) in subgroup 4(a) of the Scheme Schedule at the unit price of \$4.142, with a maximum monthly quantity of 30 units.

The Panel also noted that Dansac is to advise Stoma Associations, ostomates, Stomal Therapy Nurses and ACSA of the deletion. A period of approximately six months from the date of the Panel's recommendation (12 October 2021) should be given to allow users of the product to seek a suitable alternative and to enable Stoma Associations to manage their stock levels.

## **6. Context for Decision**

The Panel helps decide whether stoma products should be subsidised and, if so, the conditions of their subsidisation in Australia. It considers submissions in this context. A Panel decision not to recommend listing or changes to a listing does not represent a final Panel view about the merits of a particular stoma product. A company can resubmit to the Panel following a decision not to recommend listing or changes to a listing. The Panel is an advisory committee and as such its recommendations are non-binding on Government. All Panel recommendations are subject to Cabinet/Ministerial approval.

## **7. Applicant's Comment**

Dansac agrees with the SPAP recommendation.